Revvity Diagnostics Grows 11% Amid Strategic Shift to AI-Driven Platforms

Key Facts

1Revvity's Diagnostics segment saw 11% organic revenue growth while software ARR grew in the mid-20% range.

2The company achieved 13% EPS growth on 3% organic revenue growth, reflecting strong operating leverage.

Revvity's Diagnostics segment recorded 11% organic revenue growth, while software annual recurring revenue (ARR) expanded by more than 20%. Seeking Alpha reported that the company achieved a 13% increase in earnings per share (EPS) despite overall organic revenue growth of only 3%, highlighting strong operating leverage as the firm transitions into an AI-enabled diagnostics platform.

RVTY closed at $156.61 on October 21, 2026, with the stock trading between a low of $152.71 and a high of $159.48 during the session. This performance comes as the company navigates headwinds in its Life Sciences division and regional challenges in China, where recent data showed foreign direct investment (FDI) contracted by 4.3% year-over-year as of October 22, 2026.